Try our Advanced Search for more refined results
Life Sciences - January, 2024
376 articles
- Fluoride Risk Trial Opens With Claim Exposure Drops Kids' IQ
- FibroGen's $28.5M Deal With 30K Investors Nears Tentative OK
- FDA Adopts ISO Standard For Device Makers In New Rule
- Cooley-Led Vaxcyte Prices $750M Public Offering
- Cardinal Health Buys Specialty Networks In $1.2B Deal
- Norton Rose-Led FibroBiologics Pulls Off Direct Listing
- Supernus Wins Ban On Generic Seizure Treatment
- Fed. Circ. In Jan.: One Word Can Affect Claim Construction
- FDA Seeks Max Fines Against Shops Selling Esco Bars Vapes
- NJ Law Firm Seeks Sanctions In Malpractice Suit Led By Rival
- 5 Reasons Associates Shouldn't Take A Job Just For Money
- Gunderson Practice Head Boosts Orrick's Life Sciences Team
- Ex-Pfizer Compliance Officer Revamps Whistleblower Suit
- Scholars, Advocates Tell Justices Mifepristone Limits Must Go
- 1st Circ. Backs Doctor In Row Over Patent Evidence
- CDC Patent Apps Lead Gilead To Victory In HIV Research Feud
- Trans Care Ban Poses 'Philosophical' Questions, Justices Say
- Pharmacy Knew Conn. Kickbacks Broke Law, Founder Testifies
- Can Brain Scans Build On Consumer Surveys In IP Disputes?
- Philips Halts Sales Of Sleep Apnea Devices In US After Recall
- Milan Becomes 3rd Seat Of Unified Patent Court Division
- Pro Bono Patent Program Attracts Many Female Applicants
- Allergan Asks 9th Circ. To Ignore Atty's Claims Of Fraud
- 7th Circ. Won't Revive School Staffers' COVID-Testing Suit
- How Biotech Deals May Help Competition, Despite FTC View
- Expediting Psychedelics Approvals In The US And Canada
- Stryker Can't Slip California Workers' Wage Suit
- Pfizer Says Moderna Telling FDA One Thing, PTAB Another
- Troutman Pepper Gains McGuireWoods Securities Pros In NC
- Guardant Diagnostics Patent Survives PTAB Challenge
- Playing Competitive Tennis Makes Me A Better Lawyer
- CareDx Hit With $96M Infringement Verdict Over DNA Test IP
- Don't Keep Us Out Of ITC, Startup Says In Apple Watch Row
- HHS Urges Court To Reject Novo Nordisk Drug Plan Challenge
- Hearing Aid Co. Eargo Investors Ask 9th Circ. To Revive Suit
- Justices To Hear Abortion Drug Case Arguments In March
- The Top Attys In Clinton's Impeachment Trial, 25 Years Later
- Feds Drop Insider Trading Charges Against Ex-Mylan Exec
- The Pop Culture Docket: Judge Djerassi On Super Bowl 52
- 2 Biotech Firms Join IPO Fray With Plans To Raise $211M
- McCarter & English Urges Against Updating Malpractice Suit
- Reverse Merger Tips For Biotechs After SEC's Recent Actions
- Judge Might Screen Stimwave Ch. 11 Filings To Avoid 'Chaos'
- Imperative Care Names O'Melveny Deals Partner As CLO
- Catching Up With Delaware's Chancery Court
- White & Case Loses Another IP Partner To Cahill Gordon
- GSK Unit Pauses Chancery Patent Suit For Settlement Talks
- Generic-Drug Co. Concedes Infringement In Pfizer Heart Med Row
- Justices Urged To Bar Infringement Rulings After PTAB Ax
- Dissolved Biomed Co. Aims To Bar Ex-CEO's Credit Bid In Del.
- Tenn. Couple Sentenced For $65M Tricare Fraud
- Chancery Hits Hedge Fund With Sanctions In Bioverativ Case
- 2nd Circ. Backs Catholic Health System's Win In Bias Suit
- Law360 Seeks Members For Its 2024 Editorial Boards
- Panel Backs AG's Power To Nix Claims In $26B Opioid Deal
- Ex-Goodwin Procter Life Sciences Atty Joins DLA Piper In NY
- NYC Man Gets 5 Months In Merck, Pandion Insider Trading Case
- UK Litigation Roundup: Here's What You Missed In London
- Petition Watch: Patent Obviousness, ADA Trials, Spoofing
- Opioid Nuisance Query Better For W.Va. Court, 4th Circ. Hints
- Invisalign Maker Says Deal With Rival Was Lawfully Ended
- Lawmakers Push Back On Biden's Support For TRIPS Waiver
- Danaher Execs Face Investor Suit Over Post-Pandemic Slump
- Eye Care Tech Co. Gets Tentative OK For $8M DIP
- Norton Rose-Led FibroBiologics Plans Direct Listing Over IPO
- Ex-Director Says Off-Label Marketing Objections Cost Him Job
- Proposed Rule Misses The Mark On Improving MDLs
- Taking A Closer Look At Fed. Circ. Claim Construction Split
- Morgan & Morgan Beats Firms To Lead Zoll Data Breach Row
- The 7th Circ.'s Top 10 Civil Opinions Of 2023
- Employee Experience Strategy Can Boost Law Firm Success
- Med Device Employee Gets 1 Year For Forging FDA Clearance
- Latham, Cooley Steer CG Oncology's Upsized $380M IPO
- Bid To Swap Chevron For An Old Standby Raises Doubts
- Pot Insurance Suit Belongs In Federal Court, Judge Says
- Feds Ask Justices To Nix 5th Circ.'s Abortion Pill Limits
- Orrick Brings In First-Chair IP Trial Lawyer From Venable
- Amyris Says Claim Releases Needed For Post-Ch. 11 Success
- $15M Bayer Deal Gets Early Nod, But Fees Concern Judge
- Texas Judge Orders SmileDirectClub To Convert To Ch. 7
- Elmo Can't Save Parents' COVID-19 Vax Suit, 5th Circ. Says
- Florida Findings Loom Large In Del. Zantac Tort Suit
- Competing In Triathlons Makes Me A Better Lawyer
- Parsing The USPTO's Guidelines For Assessing Enablement
- Cahill Gordon Adds Life Science IP Leader From White & Case
- Notes Of Interest From 5th Circ. Illumina-Grail Merger Ruling
- UK Billionaire Joe Lewis Pleads Guilty To Insider Trading
- Danco Asks Justices To Reject 5th Circ.'s Abortion Pill Limits
- 3 Generic-Drug Cos. Reach Settlements In Price-Fixing MDL
- Wash. AG Seeks Toss Of Clinics' 'Abortion Pill Reversal' Case
- Senators Hear Praise And Worry About Patent Eligibility Bill
- Pharma Co. Must Face Investor Suit Over Cancer Drug Study
- UPenn's Retrial Bid Is Denied In $183M Birth Injury Case
- Teva Can't Escape Insurers' Copaxone Generic Delay Case
- DOJ Seeks Dismissal Of Challenge To Federal Cannabis Ban
- Del. Judge Nixes Bidder Fees In Humanigen Ch. 11
- W.Va. County To Face Off With Opioid Distributors At 4th Circ.
- Ex-CEO's Counterclaims Not Allowed, Insys Trustee Says
- DOJ's Biopharma Settlement Raises Anti-Kickback Questions
- 3 States Ask To Join High Court Case Against Abortion Drug
- Where Justices Stand On Chevron Doctrine Post-Argument
- Fed. Circ. Sends Xencor Antibody Patent Case Back To USPTO
- Precise Advance Notice Bylaws May Help Prevent Disputes
- Upsized CG Oncology IPO Could Raise As Much As $306M
- Ballard Spahr Privacy Team Co-Leader Jumps To Blank Rome
- Mayer Brown Adds Another Wilson Sonsini Litigator In Calif.
- Former Police Chief Cops To Insider Trading Charges In NY
- 2nd Circ. Backs Shkreli Lifetime Pharma Industry Ban
- 6 Practice Pointers For Pro Bono Immigration Practice
- Weil Helps Sanofi Buy Rare Diseases Co. For Up To $2.2B
- Anesthesiologists Want Quick Ruling On Medicare Calculation
- Ex-Greenberg Traurig IP Pro Joins McCarter & English
- Investors Sue Biopharma Co. After Clinical Trial Data Toss
- Mallinckrodt Trust Can Pursue Covidien Clawback Claims
- Zantac Class Attys Urge Del. Judge To Keep Experts In Case
- 3 Takeaways From Health Officials' Marijuana Proposal
- Biden Rolls Out New Abortion Protections On Roe Anniversary
- Moderna Wants UPenn Biochemist's Emails In Vax IP Dispute
- Ex-Director Denies Agreeing To Keep Pharma Firm's Info Secret
- Medical Software Co. Eye Care Leaders OK'd For Joint Ch. 11
- FTC Fights Bids To Toss Texas Anesthesia Roll-Up Case
- ESG Around The World: Canada
- Motley Rice Fights DQ Bid In Opioid MDL
- Cancer-Focused Arrivent Biopharma Eyes $150M IPO
- HIV Drug Wholesalers' Attys Get $75M In Gilead Antitrust Case
- Skin Care Drug Co. Timber Gets OK For Ch. 11 Sale To Lender
- Fish & Richardson Adds Ex-Patent Judge To Firm
- 5 Legal Considerations For Psychedelic Therapy Sector
- Catching Up With Delaware's Chancery Court
- Lessons From Country Singer's Personal Service Saga
- Red Cross Has Antitrust Immunity, Judge Rules
- Chinese Co. Can't Avoid Contempt In Philips X-Ray IP Suit
- Boston Biopharma Co. Picks Industry Veteran As Next GC
- Feds Want 30 Months For Trader In BigLaw Info Theft Case
- Sandoz To Acquire Retinal Disease Biosimilar For $170M
- Law360 Names Firms Of The Year
- Law360 Names Practice Groups Of The Year
- Claims Court Judge Doubts Takings Clause Applies To Pharma IP
- Klobuchar Tells Drug Cos. To Act On FTC Patent Warnings
- Ex-Pharmacy Head Gets 3 Years For $32M Telemed Scheme
- Kenvue Execs, J&J Face 2nd Investor Action Over FDA Probe
- Becton Investors Get Initial OK Of $85M Deal Over Recall
- Convertible Bonds Gain Momentum Amid Elevated Rates
- Feds Maintain Glycine Duty Evasion Stance, Despite New Info
- Delay In Award Boosts Philly Birth Injury Verdict To $208M
- Biotech Investor Sues In Del. For Info On 'Unfair' Repricing
- A Potential Proactive Tool For Public-Private Joint Ventures
- Winston & Strawn Dodges Sanctions In NC Pharma Fight
- Quest Diagnostics Settles Billing Practices Suit
- UK Litigation Roundup: Here's What You Missed In London
- SmileDirectClub Pushes Ch. 11 Wind-Down, Fights Ch. 7 Bids
- Stimwave's Ex-CEO Wants Bankruptcy Case Stayed
- CG Oncology Aims To Raise Up To $212M As It Sets IPO Terms
- Committee May Subpoena J&J, Merck CEOs Over Drug Costs
- Del. Court To Open Early Round In Massive Zantac Litigation
- SEC, US Trustee Object To Releases In Amyris' Ch. 11 Plan
- 7th Circuit Probes Damages Evidence In Kickback Suit
- BridgeBio Pharma Secures $1.25B For New Drug Launch
- Patent Prosecution Carries Consequences For Later Litigation
- Quinn Emanuel Says Judge Is Right To Block Subpoena
- LegitScript Wants Quick Appeal In Price-Checker Antitrust Suit
- 10 Global Antitrust Trends To Anticipate In 2024
- NanoString Says Doubled Award Would Be 'Death Sentence'
- Ex-Pfizer Worker Convicted In Paxlovid Insider Trading Case
- MoFo Says 2024 Rate Cuts Will Boost PE's M&A Appetite
- 'Chaos' Warning Resonates As Justices Mull Chevron's Fate
- Thomas Gets Laugh, Agrees Prior Ruling Is 'Embarrassment'
- 5 Key Takeaways From Supreme Court's Chevron Arguments
- FDA Can't Publish Unsupported Concerns About Pharmacy
- 10th Circ. Probes Challenge To Okla. Trans Care Ban
- Eye Care Software Co. Seeks Ch. 11 With Up To $1B Debt
- PTAB Nixes Seagen Cancer Drug IP After Daiichi Verdict
- Pharma Challenge To Advisory Anti-Kickback Opinion Tossed
- Boston's Ratio Therapeutics Raises $50M Series B For R&D
- Generic-Drug Cos. Say States Are Mum In MDL Discovery
- Judge Orders Explanation For Continuing Tylenol MDL Cases
- Sandoz Asks Fed. Circ. To Wipe Out Allergan's $39M IP Award
- Apple Drops Blood Oxygen Tech From New Watches After Ban
- Brown Rudnick Launches Life Sciences Consulting Division
- Ex-Pfizer Worker's 'Stupid' Trades Still Fraud, Jury Told
- Global Cartel Enforcement Looks Set To Intensify In 2024
- Baking Bread Makes Me A Better Lawyer
- High Court Majority Shows No Eagerness To Overturn Chevron
- J&J Consumer Inc. Hit With Neutrogena Preservatives Suit
- 6 Opinions To Read Before High Court's Chevron Arguments
- Pfizer Calls Moderna 'Willfully Naïve' In Covid Vax IP Fight
- Stimwave Trustee Seeks To Sanction Founders In Del. Ch. 11
- Jury Awards $57M To Ravgen In Genetic Test Patent Row
- Sen. Tillis Warns Biden Against Seizing Drug Patents
- Manatt Adds Health Policy Strategist In DC Office
- Apple Rips ITC, Masimo In Bid To Keep Original Watch On Sale
- Biotech Startup Alto Neuroscience Files To Go Public
- Supreme Court Amgen Ruling's Major Effect On Enablement
- Federal Courts And AI Standing Orders: Safety Or Overkill?
- Widow Targets Buchanan Ingersoll Atty In $7.5M Policy Spat
- Chancery Bars Icahn Co. Use Of Some Illumina-Grail Docs
- Crowell Adds Moses Singer Health Trio In New NYC Office
- Apple Cleared To Avoid Import Ban With Redesigned Watch
- Canada, Pharma Opposition Loom Over Fla. Drug Imports
- Vanda Asks Justices To Undo Ruling In Sleep Drug IP Case
- Conn. AG Revises Settlements For Drug Kickback Defendants
- Va. Abortion Drug Access Suit Paused For High Court Rulings
- HHS Unveils Schedule III Recommendation For Marijuana
- Apple Loses 2 Masimo Patent Challenges At Fed. Circ.
- IPO Pipeline Starts To Unclog As New Filings Gain Steam
- Vyera Ch. 11 Trustee Wants To Claw Back $10M From Supplier
- Lab Says COVID-19 Test-Maker Owes $30M Over Faulty Kits
- 7 E-Discovery Predictions For 2024 And Beyond
- Judge OKs Bid By 3 States To Join Suit Against Abortion Drug
- Drug Cos. Question FDA Off-Label Communications Guidance
- High Court Eyes Chevron Deference: What You Need To Know
- Top Considerations For Retailers Using AI To Combat Theft
- Taxation With Representation: Kirkland, Latham, Wachtell
- NJ Judge Not Convinced Epidiolex Seller Lied To USPTO
- Medicare Drug Price Talks Encourage Competition, Court Told
- Stephenson Harwood Adds 2 Partners In Hong Kong Office
- Natera Can't Escape Ravgen's Patent Infringement Suit
- Petition Watch: Atty 1st Amendment Rights, ERISA Remedies
- Quest Fertility Biz Reaches $1.25M Deal In Data Breach Case
- Eye Software Rivals Settle IP Fight Ahead Of February Trial
- Fed. Circ. Asked To Resume Ban On Apple Watch Imports
- Deals Rumor Mill: Ripple Labs, Match, Novartis
- Medtech Co. Integer To Buy Pulse Technologies For $140M
- 2 FCPA Settlements Illuminate Self-Disclosure, Disgorgement
- DOD Finds Violations Rife At White House Med Unit Pharmacy
- Union Funds Exit Amgen, Teva Antitrust MDL
- Hedge Fund Priest Seeks Atty Fees After Mixed SEC Verdict
- 2 Apple Wins Against Masimo Upheld By Fed. Circ.
- Gilead to Face 'Morally Blameworthy' Claim In HIV Drug Fight
- HHS Taps Official To Promote Competition In Healthcare
- Bill Floated To Study Bayh-Dole Requirement Inefficiencies
- Rex Medical Asks Fed. Circ. To Decry Slashing Of $10M Award
- Troutman Pepper Adds New Member To DC Health Practice
- Mass. Facility Using Once-Barred Shock Devices Sues FDA
- CNS Startup Myrobalan Therapeutics Raises $24M Series A
- AliveCor Gets PTAB To Look Into Apple Patents At Issue In Suit
- FDA Tells 5th Circ. To Toss Suit Over Kids' COVID-19 Shots
- Anti-Kickback Statute Does Not Require But-For Causation
- Fed. Circ. Affirms PTAB Rulings In Genomics Row
- FDA 'Can't Do This Alone,' Wants Help Vetting AI In Healthcare
- 'Giant Hole' In Pfizer Insider Trading Case, Jury Told
- NJ Lab, Owner To Pay $13M To Settle Kickback Claims
- Class Claims Aren't About Food Fraud, NJ Justices Say
- 5 Litigation Funding Trends To Note In 2024
- Vape Distributor Can't Get Quick Win In Contract Dispute
- Texas Atty Beats Perjury Convictions, But Other Counts Stand
- FDA Digital Tech Rule Faces Health Privacy, Inequity Test
- Ohio High Court Urged To Toss $650M Opioid Verdict
- VC Firm Expands Collaborations In New Tech Initiative Debut
- Amyris Fights Claims In Cannabis IP Row By Defining 'Under'
- Deal Language Irks Judge As $11M False Claims Trial Begins
- HHS Updates Religious, Moral Objection Rule For Doctors
- Health Groups Urge Texas Justices To Nix Trans Youth Care Ban
- Biopharma Co. Can't Dodge Secrets Row Over Detox Drug
- Home Health Co. Faces ERISA Suit Over Smoking Surcharge
- Air Force Can Sole-Source Medical Infusion Pump Updates
- USPTO Affirms Amgen Ruling Didn't Alter Experimentation Test
- Attys Seek $95M Fees For Philips CPAP Economic Loss Deal
- Medtronic's Cautionary Tale Of Fed. Circ. Word Limits
- GSK Agrees To Buy US Respiratory Drug Biz For Up To $1.4B
- Supreme Court Is Suddenly Embroiled In A Term For The Ages
- Senators To Probe Pharma Cos. On 'Outrageous' Inhaler Costs
- Teva, Israeli Investors End Investor Suit Over Opioid Scandal
- Future Apple Watch Sales Hinge On Next Steps In Patent Row
- Proskauer Picks Up IP Partner From Frankfurt Kurnit
- Baker Botts Bond Took Antitrust Pros To Wilson Sonsini
- FDA Advice Prompts Shareholder Suit Against J&J, Execs
- Key Legal Trends For Healthcare And Life Sciences In 2024
- Catching Up With Delaware's Chancery Court
- Humanigen Gets Access To New Cash For Ch. 11 Process
- Merck Lands Cancer Fighter Harpoon Therapeutics For $680M
- Pharma Co. Overstated Unpatented Drug's Value, Suit Says
- Novartis To Buy Merck Spin-Off Calypso Biotech For Up To $375M
- Eli Lilly, Novartis Could Pump Close To $3B Into AI Drug Tech
- ImmunoGen Undervalued In AbbVie Deal, Shareholder Claims
- Ex-Dechert Litigator Joins Seeger Weiss In Philadelphia
- Walgreens, Humana Cut $360M Deal Ending Crowell Fight
- ESG Around The World: South Africa
- Biofuel Co. Ryze Gets OK On Ch. 11 Wind-Down Plan
- Cravath Steers J&J Buy Of Skadden-Led Ambrx In $2B Deal
- Boston Scientific To Buy Medtech Co. Axonics In $3.7B Deal
- GE HealthCare To Buy AI-Powered MIM Software
- Justices Won't Take Up DOD, Ex-Sergeants Vax Mandate Spat
- Justices Refuse To Eye PTAB's Fintiv Review Denial Policy
- Idaho AG Again Denied Immunity In Abortion Travel Ban Fight
- Drug Kickback Case Lineup In Flux As Trial Looms
- Eli Lilly Goes Straight To Consumers With Telehealth Platform
- Pharma Co. Snags $100M To Advance Psychedelic Treatment
- Split 9th Circ. Revives Antitrust Suit Against Catheter Maker
- Sarepta Avoids IP Claims As Judge Finds UPenn Patent Invalid
- Boehringer Ingelheim Inks €410M Deal With Kyowa Kirin
- 9th Circ. Won't Rethink FCA Disclosure Ruling Against Valeant
- NJ Brothers Ordered To Prison For Prescription Drug Scheme
- Philips Blames SoClean For Breathing Machine Breakdowns
- Attys Hopeful For Deals Pickup As JPMorgan Event Kicks Off
- Former Alexion Exec Avoids Prison In Insider Trading Case
- FOIA Exemption Questions On Redacted HHS Cannabis Letter
- Fed. Circ. Ruling Seemingly Offers PTAB Deadline Immunity
- Evaluating Retroactivity Of Mich. Drugmaker Immunity Repeal
- 4 Legal Ethics Considerations For The New Year
- McCarter & English Accused Of Obstructing Malpractice Case
- FTC Rite Aid Order Holds Biometrics And AI Compliance Tips
- Bribery Settlement Gives Insight On DOJ Policies
- SEC Case May Expand Scope Of Insider Trading Liability
- UK Litigation Roundup: Here's What You Missed In London
- Fla. Becomes 1st State To Win FDA Approval To Import Drugs
- Where Psychedelics Policy Is Going In 2024
- No Evidence Of Harm: ITC Denied Apple's Watch Ban Stay
- Birth Control Clips Hurt Women When They Move, Suit Says
- Humanigen Hits Ch. 11 After COVID Drug Denied Authorization
- Roche Could Pay $2B In Deal To Develop Potent Cancer Drugs
- Small Vape Cos. Ask Court To Block FDA Premarket Rule
- Life Sciences Investment Firm TCG Crossover Closes $1B Fund
- 2 Couples Sue CooperSurgical After Embryo Solution Recall
- LegitScript Can't Nix PharmacyChecker Antitrust Suit
- Waiving COVID-19 IP Protections Would Harm US Industry
- Assisted Living Brass May Have Caused Late Suit, Judge Says
- McCarter & English Rips Bid To Bring New Malpractice Claims
- Ex-Shook Hardy IP Pro Named USPTO's Chief Policy Officer
- Chancery Rejects Injunction Barring SomaLogic Merger Vote
- Ex-CEO Of Texas Biotech Co. Sues It In Del. For Legal Fees
- Deals Rumor Mill: Cigna, Bain Capital, Amazon
- Fed. Circ. Patent Decisions In 2023: An Empirical Review
- What The Law Firm Of The Future Will Look Like
- Medical Tech Co. Buys Breathing Device Biz For Up To $2.5M
- Judge Won't Dismiss Botox Trade Secret Dispute
- Univ. Of Pittsburgh Sued By Fired Worker Who Flagged Safety
- Galderma Labs Seeks OK Of Award Over Botox-Like Treatment
- Sporting Goods Co. Can't Shake Football Helmet Patent Case
- Wellness Co. Sues Theragun Maker For Patent Infringement
- Chancery Mulls Call To Block $1B SomaLogic Merger
- Esperion Snags $125M Deal With Daiichi On Cholesterol Drug
- Conn. AG, Alleged Drug Kickback Ringleader Ink $230K Deal
- Judge Pauses Apple Patent Suit Ahead Of PTAB Decision
- BioXcel Execs Face Investor Suit Over Alzheimer's Drug Probe
- 10th Circ. Denies Okla. Stay Request In PBM Law Fight
- 4 PR Pointers When Your Case Is In The News
- Hemp Industry Urges Congress To Make Policy Changes
- Witness On Hair Loss, Rashes DQ'd In Flint Case As Unreliable
- FDA Seeks Comment On Ideas To Improve Agency Guidance
- Fed. Circ. Backs Refusal To Block Abbott IPRs Of DexCom IP
- Digging Into The Debate On FDA's Proposed Lab Test Rule
- Myovant, Sumitomo Beat Investor Suit Over Skadden Advice
- Medicare Fraud Player Slams Feds' 'Excessive' Prison Ask
- Lye Buyers Denied Class Cert. In $861M Price-Fixing Fight
- Health Service Co., Oncology Firm Kick-Start 2024 IPO Filings
- You Can't Double Dip The Patents, Judges Told
- HHS OIG Won't Levy AKS Fines For Subsidies In Clinical Trial
- Teva Can't Block Colo. EpiPen Program Over Takings Claim
- Regulators Approve NYSE Plan To Ease Rules On Equity Sales
- How 2023 Shaped Drug And Medical Device Legal Trends
- UK Biopharmaceutical Biz Raises $260M In Series C Funding
- Catching Up With Delaware's Chancery Court
- Pa. Court Rejects Red Book Drug Prices For Workers' Comp
- Consumer Health Activist And Author Sidney Wolfe Dies At 86
- What Insurers Gain When Litigating Coverage Denials
- Trending At The PTAB: 6 Areas To Watch In 2024
- Infant Formula Recalled After Possible Contamination
- Chancery Dissolves Biomed Co. For 'Egregious' Conduct
- 5 Trends That Will Affect Food Litigation In 2024
- New Hampshire Residents Nab Class Cert. In PFOA Suit
- Patent Litigation Trends To Watch In 2024
- 5 Supreme Court Cases To Watch This Spring
- Patent Policy To Watch In 2024
- Law Firm Strategies For Successfully Navigating 2024 Trends
- Michigan Cases To Watch In 2024
- Bankruptcy Issues To Watch In 2024
- Will The DOJ Reschedule Cannabis In 2024?
- Patent Cases To Watch In 2024
- Product Liability Regulation And Legislation To Watch In 2024
- Trials To Watch In 2024
- Top North Carolina Cases To Watch In 2024
- Product Liability Cases To Watch In 2024
- Connecticut Cases To Watch In 2024
- Appellate Outlook: Circuit Splits & Hot Topics To Track In 2024
- 'Pent Up' Demand For IPOs Could End Drought In 2024